Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.
نویسندگان
چکیده
Thrombin bound to a fibrin clot remains active and poorly accessible to heparin-AT III complex. During fibrinolysis, thrombin is released as thrombin-FDP complex and is inactivated by heparin-AT III. However, as successive fibrin layers are removed, inaccessible molecules of thrombin are exposed at the surface of the residual clot, possibly contributing to the occurrence during thrombolytic therapy of coagulation that is poorly controlled by heparin. We have investigated the accessibility of fibrin-bound thrombin to hirudin. The results clearly show that two recombinant hirudin variants neutralize thrombin both in solution and fibrin bound. Furthermore, we have found that in in vitro models, hirudin present in the surrounding medium of a clot under lysis is more efficient than heparin in preventing the activation of coagulation. This observation suggests that hirudin may be effective in the prevention of the rethrombotic process frequently encountered during thrombolytic therapy.
منابع مشابه
Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy.
To evaluate the effect of thrombin on the dynamics of thrombolysis, we infused rabbits with heparin or hirudin alone or in conjunction with tissue-type plasminogen activator (t-PA) and monitored the kinetics of fibrinolysis and changes in ex vivo platelet aggregation responses over time. Both heparin and hirudin enhanced total fibrinolysis in an ex vivo arteriovenous shunt preparation: 82 +/- 2...
متن کاملTrials and tribulations of thrombin inhibition.
Trials and tribulations of thrombin inhibition Thrombin is a central component in the molecular and cellular response to plaque rupture and therefore pertinent to the entire spectrum of acute coronary syndromes. This serine protease not only promotes the deposition of fibrin strands and further activation of the coagulation cascade, but is also a potent stimulus for platelet activation, inducti...
متن کاملSafet Observations From the Pilot Phase of the Randomized r-Hirudin for Improvement of Thrombolysis (HIT-Ill) Study A Study of the Arbeitsgemeinschaft Leitender
Background Adjunctive therapy for thrombolysis in acute myocardial infarction consists of platelet inhibition with aspirin and thrombin inhibition with heparin. Thrombin inhibition may be improved by the use of hirudin as indicated by experimental and phase II clinical studies. The randomized, double-blind phase III r-Hirudin for Improvement of Thrombolysis study (HIT III) compared a recombinan...
متن کاملRelative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
BACKGROUND Optimal coronary thrombolysis should be prompt and persistent. Although activation of platelets and increased thrombin activity have been associated with clinical thrombolysis, the role of each in delaying thrombolysis or inducing early coronary reocclusion has been difficult to define. METHODS AND RESULTS In conscious dogs with coronary thrombosis induced by electrical current, we...
متن کاملPlasminogen Activation With Streptokinase
Background. Platelet activation occurs in vivo during pharmacologic thrombolysis and may contribute to recurrent thrombosis. Plasmin does not directly activate platelets except at high concentrations; thus, the mechanisms for platelet activation during thrombolysis remain undefined. Increases in thrombin activity also occur in patients treated with fibrinolytic agents and may contribute to acti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Blood
دوره 74 3 شماره
صفحات -
تاریخ انتشار 1989